Schizophrenia drug gains new indication for maintenance treatment

November 21, 2007

Seroquel XR from AstraZeneca has gained a new indication: for maintenance treatment of schizophrenia in adults

AstraZeneca's Seroquel XR (quetiapine fumarate) Extended-Release Tablets have been approved for maintenance treatment of schizophrenia in adult patients. This follows an earlier approval, in May, for acute treatment of schizophrenia in adult patients. The Wilmington, Del., firm explained that schizophrenia patients often suffer relapses, so Seroquel XR will provide a new long-term treatment option for them.

Click here to see more articles from Drug Topics Daily News.

To go to the Drug Topics homepage, click here.

Related Content:

Community Practice | News